Sanara Medtech Company Top Insiders
SMTI Stock | USD 35.94 0.42 1.16% |
Sanara Medtech's insiders are aggressively selling. The analysis of insiders' sentiment of trading Sanara Medtech stock suggests that almost all insiders are panicking at this time. Sanara Medtech employs about 107 people. The company is managed by 15 executives with a total tenure of roughly 21 years, averaging almost 1.0 years of service per executive, having 7.13 employees per reported executive.
Shawn Bowman President President Wound Care Division |
Zachary Fleming President President Surgical Division |
Sanara Medtech's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2022-11-08 | Zachary B Fleming | Disposed 417 @ 33 | View | ||
2022-11-04 | Zachary B Fleming | Disposed 563 @ 33 | View | ||
2022-11-02 | Zachary B Fleming | Disposed 20 @ 33.02 | View | ||
2022-09-22 | Shawn M Bowman | Disposed 1000 @ 27.89 | View | ||
2022-07-05 | Zachary B Fleming | Disposed 265 @ 21.45 | View | ||
2022-06-28 | Zachary B Fleming | Disposed 69 @ 21 | View | ||
2022-06-24 | Zachary B Fleming | Disposed 457 @ 21 | View | ||
2022-06-17 | Shawn M Bowman | Disposed 1000 @ 20.02 | View |
Monitoring Sanara Medtech's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Sanara |
Sanara Medtech's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Sanara Medtech's future performance. Based on our forecasts, it is anticipated that Sanara will maintain a workforce of under 110 employees by January 2025.Sanara Medtech Management Team Effectiveness
The company has return on total asset (ROA) of (0.0508) % which means that it has lost $0.0508 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2028) %, meaning that it created substantial loss on money invested by shareholders. Sanara Medtech's management efficiency ratios could be used to measure how well Sanara Medtech manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.18. The current Return On Capital Employed is estimated to decrease to -0.07. As of now, Sanara Medtech's Total Current Assets are increasing as compared to previous years. The Sanara Medtech's current Intangible Assets is estimated to increase to about 47.2 M, while Non Currrent Assets Other are forecasted to increase to (18.1 M).The Sanara Medtech's current Common Stock Shares Outstanding is estimated to increase to about 8.7 M, while Net Loss is forecasted to increase to (6.8 M).
Sanara Medtech Workforce Comparison
Sanara Medtech is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 97,707. Sanara Medtech adds roughly 107 in number of employees claiming only tiny portion of equities under Health Care industry.
Sanara Medtech Profit Margins
The company has Profit Margin (PM) of (0.11) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.06) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.06.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.92 | 0.8792 |
|
|
Sanara Medtech Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sanara Medtech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sanara Medtech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Sanara Medtech insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-03-01 | 0.2857 | 2 | 7 | 17,343 | 5,075 |
2023-06-01 | 10.0 | 10 | 1 | 38,766 | 1,000.00 |
2023-03-01 | 0.5 | 4 | 8 | 15,351 | 4,599 |
2022-09-01 | 2.6667 | 8 | 3 | 37,704 | 1,750 |
2021-12-01 | 0.2222 | 4 | 18 | 13,843 | 7,275 |
2021-09-01 | 1.0 | 1 | 1 | 5,339 | 1,000.00 |
2020-03-01 | 1.8333 | 33 | 18 | 5,096,143 | 2,362,193 |
2019-12-01 | 1.5 | 3 | 2 | 1,204,820 | 0.00 |
2018-03-01 | 2.0 | 6 | 3 | 70,270,577 | 29,852 |
2016-06-01 | 1.0 | 1 | 1 | 1,500,000 | 1,500,000 |
2015-03-01 | 1.0 | 1 | 1 | 750,000 | 750.00 |
2004-12-01 | 1.0 | 3 | 3 | 36,250 | 36,250 |
2004-09-01 | 8.0 | 8 | 1 | 7,733,553 | 3,750 |
Sanara Medtech Notable Stakeholders
A Sanara Medtech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Sanara Medtech often face trade-offs trying to please all of them. Sanara Medtech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Sanara Medtech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Ronald Nixon | Executive Chairman of the Board | Profile | |
Shawn Bowman | President Wound Care Division | Profile | |
Seth Yon | President Commercial | Profile | |
David Strasfeld | President Healing | Profile | |
Zachary Fleming | President Surgical Division | Profile | |
Rebecca Mcmahon | President Development | Profile | |
Michael McNeil | CFO Secretary | Profile | |
Bill Fitzgerald | Compliance Officer | Profile | |
Jacob Waldrop | Chief Officer | Profile | |
Callon Nichols | Director Relations | Profile | |
Jane Fore | Chief Officer | Profile | |
Tricia Matteson | Director Marketing | Profile | |
Tyler Palmer | Chief Officer | Profile | |
Carla Day | Director Services | Profile | |
FACHM FAPWCA | Pres Services | Profile |
About Sanara Medtech Management Performance
The success or failure of an entity such as Sanara Medtech often depends on how effective the management is. Sanara Medtech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Sanara management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Sanara management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.17) | (0.18) | |
Return On Capital Employed | (0.07) | (0.07) | |
Return On Assets | (0.06) | (0.06) | |
Return On Equity | (0.10) | (0.10) |
Sanara Medtech Workforce Analysis
Traditionally, organizations such as Sanara Medtech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Sanara Medtech within its industry.Sanara Medtech Manpower Efficiency
Return on Sanara Medtech Manpower
Revenue Per Employee | 607.4K | |
Revenue Per Executive | 4.3M | |
Net Loss Per Employee | 40.2K | |
Net Loss Per Executive | 286.9K | |
Working Capital Per Employee | 49K | |
Working Capital Per Executive | 349.2K |
Complementary Tools for Sanara Stock analysis
When running Sanara Medtech's price analysis, check to measure Sanara Medtech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanara Medtech is operating at the current time. Most of Sanara Medtech's value examination focuses on studying past and present price action to predict the probability of Sanara Medtech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanara Medtech's price. Additionally, you may evaluate how the addition of Sanara Medtech to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |